Kornimate/medical-research-clean huggingface dataset:
glucagon-like peptide 1 receptor agonist in acute large vessel occlusion stroke after endovascular treatment

Conditions: Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment

Summary: the goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (ais). it will also learn about the safety of semaglutide in ais. the main question it aims to answer is: does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (evt)? researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with evt. participants will: * receive 0.5mg semaglutide injection before (day 0) and 1 week (day 7) after evt , or evt alone. * have additional blood test before and after evt. * receive neurological assessment before evt, day 1, day 3, day 5-7 after evt or on hospital discharge (whichever earlier), day 90±14 after evt. audio or video of the assessment may be recorded if possible. * receive brain ct + ct angiogram + ct perfusion and mri after evt, where the ct scan may be repetitive.


Eligibility criteria:
inclusion criteria: 1. lvo stroke at terminal ica, m1 or dominant m2 with an lkw-to-randomization ≤24 hours 2. age ≥ 18 years old 3. national institute of health stroke scale ≥ 6 at the time of brain imaging 4. acute lvo stroke due to thromboembolism or intracranial stenosis 5. patients who received computer tomographic or magnetic resonance angiography 6. aspects ≥ 6 for patients with lkw-to-randomization ≤6 hours 7. salvageable ischemic penumbra demonstrated by ct perfusion or mri for patients with lkw-to-randomization between 6 and 24 hours 8. informed consent obtained from patient or acceptable patient surrogate. exclusion criteria: 1. use of intravenous thrombolytic therapy (alteplase or tenecteplase) 2. pre-stroke mrs \> 2 for patients \ 1 for patients ≥ 80 years old 3. intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas) 4. simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation 5. unstable hemodynamics on presentation that require resuscitation 6. systolic blood pressure \>185mmhg or diastolic blood pressure \>110mmhg that cannot be controlled by antihypertensive drugs 7. severe comorbid illness, e.g. terminal malignancy with life expectancy \<1 year 8. pregnant or lactating female 9. participation in another clinical trial 10. contraindications to glp1-ra, including history of allergy to glp-1ra, family or personal history of multiple endocrine neoplasia, medullary thyroid or pancreatic carcinoma, or proliferative diabetic retinopathy 11. blood glucose \ 22.2 mmol/l; platelet count \ 1.7 12. patients with known estimated glomerular filtration rate of \ 3mg/dl (265.2µmol/l); chronic liver disease with child's pugh score c or above; or recurrent unexplained hypoglycemia. 13. suspected or confirmed vasculitis of the central nervous system 14. unable to complete 90-day follow-up assessment
initial treatment with bevacizumab in choroidal neovascularization associated to high myopia

Conditions: Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia

Summary: the purpose of this protocol is to determine wether the initial protocol in the treatment of subfoveal choroidal neovascularization associated to high myopia with bevacizumab intravitreal injections is more effective when using 3 doses vs using 1 single dose in the load period


Eligibility criteria:
inclusion criteria: * active subfoveal/juxtafoveal choroidal neovascularization in high myopia confirmed by fundus fluorescein angiography and optical coherence tomography * best corrected visual acuity loss with less than 6 months of evolution, caused mainly by the neovascular lesion (based in investigator´s criteria) * no atrophy or fibrotic component that may prevent visual acuity improvement * patients previously treated with photodynamic therapy are allowed to participate in this study * signed informed consent * signed data protection consent * negative pregnancy test in potential childbearing women at screening, with accepted contraceptive method during the whole study exclusion criteria: * previous vitreous surgery in study eye * tractional maculopathy or epiretinal membrane found in optical coherence tomography * media opacities that may prevent correct fundus assessment * lack of posterior capsule integrity in pseudophakic patients * patients with great possibilities of not being able to attend to study visits / follow visit procedures (investigator´s criteria) * patients previously treated with intravitreal antiangiogenic injections

Keywords: high myopia choroidal neovascularization
oral peptones load in normocalcemic and hypercalcemic primary hyperparathyroidism and healthy subjects

Conditions: Hyperparathyroidism; Hypercalcemia

Summary: the purpose of this study is to assess if subjects with hyperparathyroidism with normal serum calcium levels have different responses in the calcium regulating hormonal handling compared to a) patients with primary hyperparathyroidism and high serum calcium levels; b) healthy subjects. the differences will be evaluated with oral peptones load and subsequent blood samples collected every 15 minutes for two hours. ionized calcium, phosphate, gastrin and pth levels will be evaluated.


Eligibility criteria:
inclusion criteria: 1. normocalcemic hyperparathyroidism * presence of high serum levels of intact pth * serum ionized calcium levels in the high normality range 2. hypercalcemic hyperparathyroidism * presence of high serum levels of intact pth * high serum ionized calcium levels exclusion criteria: 1. potential causes of secondary hyperparathyroidism like renal insufficiency, liver disease, malabsorption, hypercalciuria, paget's disease, thiazide diuretic or lithium use. 2. bone disease of any origin

Keywords: receptors, calcium sensing parathyroid hormone
first in human study of torl-3-600 in participants with advanced cancer

Conditions: Advanced Solid Tumor; Colorectal Cancer

Summary: this first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of torl-3-600 in patients with advanced cancer


Eligibility criteria:
inclusion criteria: * advanced solid tumor * measurable disease, per recist v1.1 * eastern cooperative oncology group (ecog) performance status 0-1 * adequate organ function exclusion criteria: * has not recovered \[recovery is defined as nci ctcae, version 5.0, grade ≤1\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements * received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of torl-3-600 * progressive or symptomatic brain metastases * serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection * history of significant cardiac disease * history of myelodysplastic syndrome (mds) or aml * history of another cancer within 3 years before day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. a history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (dcis) of the breast and prostate cancer with a gleason score less than or equal to 6, are also not excluded * if female, is pregnant or breastfeeding
randomized controlled phase ii trial of pre-operative celecoxib treatment in breast cancer

Conditions: Breast Neoplasms; Breast Cancer

Summary: cyclooxygenase-2 (cox-2) is frequently over-expressed in primary breast cancer. there is evidence that cox-2 inhibition exerts anti-tumor effects in breast cancer. to further determine the effect of cox-2 inhibition in primary breast cancer, we aimed at studying the changes in breast cancer tissues of patients treated with the selective cox-2 inhibitor celecoxib. in a single-centre double-blinded phase ii study, breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) or placebo twice daily for two to three weeks. we collected fresh-frozen pre-surgical biopsies (before treatment) and surgical excision specimens (after treatment) to assess the tumor changes by use a cdna microarray, which allows to study the genome-wide changes at the transcriptional level.


Eligibility criteria:
inclusion criteria: * female patients suspected of having invasive breast cancer, \>1 cm in diameter, and in whom there is an indication for a core or incision biopsy * age \<75 years at time of diagnosis * patient willing and able to comply with the study prescriptions * patient able to give written informed consent before patient registration/randomisation * pre- and post-menopausal patients are eligible * hormone receptor positive and negative patients are eligible * a negative pregnancy test in pre-menopausal women exclusion criteria: * hiv, hbv or hcv positivity * known hypersensitivity to nsaids * a history of upper gastro-intestinal bleeding * endoscopically proven upper gastro-intestinal ulceration * patients using nsaids, including salicyclic acid * systemic use of corticosteroids * a history or the presence of any other malignancy excepting adequately treated squamous cell skin cancer or in situ carcinoma of the cervix * patients who have been treated with neo-adjuvant chemotherapy or hormone therapy

Keywords: celecoxib clinical trial, phase ii oligonucleotide array sequence analysis
evaluation of ultrasound for detecting hip impingement

Conditions: Femoroacetabular Impingement

Summary: patients are being asked to participate in this study because a previous research mri of their hips showed that the shape of the head of their thigh bone may indicate fai of the hip. we have already collected cartilage imaging data and data on how the hip joint moves on people with painful/symptomatic fai and people with normal hip function. we would now like to compare the motion of the hip joint to those with painful fai using ultrasound.

hip impingement is thought to be a leading cause of hip osteoarthritis, and occurs due to deformities in the hip joint. however some individuals have these deformities but do not exhibit symptoms. using the standard magnetic resonance imaging and clinical tests it is not clear which deformities will cause degeneration, requiring surgical intervention. we propose to evaluate the deformity and impingement between the femur and acetabulum using dynamic ultrasound imaging. ultrasound does not involve radiation and can acquire video of the hip joint and is thus suitable for such diagnostic purposes. in this pilot study we will evaluate the feasibility of ultrasound in diagnosing hip impingement.

Eligibility criteria:
inclusion criteria: surgical group: * hip pain longer than 6 months referred to the groin/lateral aspect of the hip * positive impingement sign plain radiographs: * absence of arthritis (tonnis grade 0 or 1) * absence of dysplasia (center edge \>25 degrees) on anterior-posterior radiograph * α-angle greater than 60 degrees on mri. exclusion criteria: * patients who don't meet inclusion criteria * control group: subjects with hip pain or with alpha angle \> 50 degrees on mri

Keywords: femoroacetabular impingement morphometry dynamic magnetic resonance imaging ultrasound screening diagnosis
phitys i™ percutaneous left ventricular assist system study

Conditions: Coronary Artery Disease

Summary: the primary purpose of this clinical trial is to evaluate the safety and efficacy of the percutaneous left ventricular assist system versus intra-aortic balloon pump (iabp) for circulatory support during high-risk pci.

this prospective, multi-center, randomized controlled clinical trial of the percutaneous ventricular assist system is designed to measure the incidence of freedom from major adverse cardiovascular and cerebrovascular events (macce) at 30 days after pci.

Eligibility criteria:
inclusion criteria: 1. 18 years old≤ patient age ≤90 years old and patient is not in pregnancy or lactation; 2. patients who have been evaluated by two or more cardiovascular surgeons as unsuitable for conventional surgery; or patients who have refused conventional surgery after adequate communication from the surgeon and who are at high risk for conventional surgery; 3. left ventricular ejection fraction (lvef) ≤ 35% and at least one of the following criteria: * intervention on the last patent coronary conduit, or * intervention on an unprotected left main coronary artery or b) lvef ≤ 30% and intervention in patient presenting with triple vessel disease. 4. patient who can understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups. exclusion criteria: 1. pre-procedure cardiac arrest within 24 hours of enrolment requiring cpr; 2. pre-procedure st-segment myocardial infarction within 24 hours of enrolment; 3. patient is in cardiogenic shock; 4. mural thrombus in the left ventricle; 5. post-infarction ventricular septal rupture, or atrial septal or ventricular septal defects; 6. the presence of mechanical aortic or mitral valve or heart constrictive device; 7. the presence of aortic stenosis (aortic orifice area ≤1.5cm²)； 8. the presence of moderate to severe aortic or mitral or tricuspid insufficiency; 9. the presence of severe peripheral vascular disease that would preclude the placement of the percutaneous mechanical circulatory assist device; 10. severe aortic diseases such as aortic dissection and aortic aneurysm; 11. active infective endocarditis or other active infections; 12. chronic renal insufficiency (creatinine clearance≤30ml/min); 13. liver dysfunction (elevation of liver enzymes and bilirubin levels to ≥3xuln or inr≥2); 14. the presence of uncorrectable abnormal coagulation (platelet count≤75,000/mm\^3 or inr≥2.0 or fibrinogen≤1.50 g/l); 15. the presence of uncorrected moderate to severe anemia (hemoglobin \<90 g/l); 16. history of stroke or tia within 1 month of enrolment; 17. allergy or intolerance to contrast media, anticoagulant and antiplatelet drugs (e.g., bivalirudin, low molecular heparin, aspirin, clopidogrel, ticagrelor, etc.); 18. participation in clinical trials of other drugs or medical devices prior to enrollment that have not yet reached the primary outcome of research; 19. patient with poor compliance and could not complete the study as required determined by the investigator.
quality of life of children born very preterm at school-age

Conditions: CHILDREN BORN VERY PRETERM AT SCHOOL-AGE

Summary: aims the aims were 1) to describe the quality of life (qol) of a cohort of children born very preterm (\<28 weeks of gestation) aged 7 to 9 years; 2) to compare children's qol to the qol reported by a french general population of reference. 3) to determine whether socio-demographic factors, neonatal features and neurocognitive status were impacting their qol. methods: * multi-centre study: 6 french level three perinatal care units (marseille, montpellier, nantes, nîmes, nice and rouen). * inclusion criteria: all infants born before 28 weeks of gestation between january 2005 and december 2007, from 7 to 9 years old of age at the time of evaluation. * written agreement to participate: collected from parents. * data collection: reports of children's qol by children and their parents (using standardized validated questionnaires); clinical information about the children, obtained through a medical examination; children neurocognitive profile. * duration of inclusion: over 24 months. * population: of the six structures, approximately 300 children will be evaluated consistent with the active files of the participating centres and an attrition rate of 30%. perspectives this is one of the first studies to collect self-reported data on quality of life of school-age children (7-9 years) born before 28 weeks of gestation. a better understanding of demographic and clinical determinants of qol of school-age very preterm children may help clinicians involved in the care of these children in their ethical and medical considerations.


Eligibility criteria:
inclusion criteria: * child been born between 01/01/2005 and the inclusive 31/12/2007, * extreme premature born child before 28 weeks of amenorrhea, * child hospitalized after the birth in a level maternity 3 (been born " inborn " or " outborn ") * not dead child, * child not presenting a cerebral palsy, * child capable of answering a questionnaire in french language, * child among whom the parents(relatives) or the legal representatives accepted the principle of the participation in this study, and having signed a consent, * child granting to participate in the study. exclusion criteria: * child died between the birth and dates her(it) evaluation, * child presenting a cerebral palsy * child among whom the parents(relatives) or the legal representatives refused that their child participates in this study
part two of novel adoptive cellular therapy with sars-cov-2 specific t cells in patients with severe covid-19

Conditions: COVID-19

Summary: the overall objective of this project is to develop an emergent treatment protocol using adoptive t-cell therapy for the treatment of severe covid-19. the central hypothesis is that sars-cov-2 specific t cells from convalescent donors who have recovered from covid-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe sars-cov-2 infections.

a novel severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is the cause of coronavirus disease 2019 (covid-19). currently, no vaccine has been proven to be effective. while waiting for vaccine to be developed, passive immunity can be acquired immediately by adoptive transfer of sars-cov-2 specific t cells from convalescent donors into newly infected patients. the overall objective of this project is to develop an emergent treatment protocol using adoptive t-cell therapy for the treatment of severe covid-19. the central hypothesis is that sars-cov-2 specific t cells from convalescent donors who have recovered from covid-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe sars-cov-2 infections. part two of this project is to assess the safety and efficacy of these t cells in patients with covid-19.

Eligibility criteria:
inclusion criteria: * age 1 to 90 years * tested positive for sars-cov-2 \<72 hours prior to enrolment * predicted to have high chance of mortality: group 1: severe disease, defined by one or more of the following: * dyspnea * respiratory frequency ≥ 30/min * blood oxygen saturation ≤ 93% * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 * lung infiltrates \> 50% within 24 to 48 hours * respiratory failure * septic shock * multiple organ dysfunction or failure group 2: mild to moderate disease, at high risk of progression to severe disease. for example, * age \> 65 years * chronic health conditions such as chronic lung disease, cardiovascular disease, diabetes mellitus, obesity, end-stage renal disease or liver disease exclusion criteria: * rapidly progressive disease with anticipated life-expectancy \<72 hours * receiving steroid (\>0.5mg/kg methylprednisolone equivalent) * pregnancy * breastfeeding
cognitive function after radiation therapy for brain tumours

Conditions: Primary Brain Tumor; Radiation Toxicity

Summary: this study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (rt). all types of brain tumours apart from glioblastoma will be included

rt to brain tumours causes cognitive dysfunction. the extent of rt induced changes in cognitive function and radio-sensitivity of the brain is unknown. rt with protons instead of photons spares the healthy brain tissue more and is believed to reduce the risk of cognitive dysfunction. there is modest knowledge on which parts of the brain the investigators need to spare, to prevent cognitive dysfunction. the study is a cross sectional study assessing cognitive function in patients with brain tumours previously treated with rt compared to a similar non irradiated group. 104 patients with specified brain tumours from aarhus university hospital treated in the period 2006-2016 will be included. the patients will do patient reported outcome (pro) and undergo neuropsychological assessment with standardized tests: they will do this prior to rt treatment and ½, 1, 3 and 5 years afterwards. the pro's included measures on quality of life, fatigue, sleep, depression, anxiety, and socio demografica. the standardized tests are: trail making test (tmt); hopkins verbal learning test (hvlt); controlled oral word association test (cowat) - animals and s; coding and digit span from wais-iv; paced auditory serial addition test (pasat). the correlation between cognitive scores and rt dose-volume parameters to specific areas in the brain will be tested.

Eligibility criteria:
inclusion criteria: * the participant must be 18 years or older and danish speaking. * performance status 0-2 * capable of cooperating on testing * diagnosed with one of the following diagnoses according to who 2016 classification 16 and been treated between 2006 and 2016 1. zm93803 glioma (exclusive glioblastoma) 2. zm9401/3 anaplastic astrocytoma, idh mutant 3. zm9400/3 diffuse astrocytoma, idh-mutant 4. zm9411/3 gemistocytisk astrocytoma, idh mutant 5. zm9400/3 diffuse astrocytoma, nos 6. zm9451/3 anaplastic oligodendroglioma, idh mutant and 1p/19q-co deleted 7. zm9450/3 oligodendroglioma, idh mutant and 1p/19q-co deleted 8. zm9450/3 oligodendroglioma, nos 9. zm9451/3 anaplastic oligodendroglioma, nos 10. zm9530/0 meningioma 11. zm9470/3 medulloblastoma, nos 12. dd352a pituitary adenoma 13. other rare brain tumours including skull base sarcomas - exclusion criteria: performance status 3-4 progression after radiation therapy -

Keywords: cognitive function